Information Hub

Clinical News

2018-12-04

Olaparib significantly improves PFS in BRCA-mutated ovarian cancer as frontline maintenance therapy

In the phase 3 SOLO-1 study, olaparib as frontline maintenance therapy showed significant PFS improvement in ovarian cancer patients carrying BRCA mutation

Source:

N Engl J Med

2018-12-04

Rucaparib shows encouraging anti-tumor activity in metastatic castration-resistant prostate cancer with a deleterious BRCA alteration

According to the preliminary data of TRITON2 study, rucaparib showed anti-tumor activity in metastatic castration-resistant prostate cancer patients carrying BRCA mutation.

Source:

Annals of Oncology

2018-12-04

FDA granted accelerated approval of lorlatinib in ALK+ NSCLC

Based on data from a phase II study (B7461001), the FDA approved lorlatinib for the treatment of patients with ALK positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs)

Source:

FDA

2018-12-04

Infigratinib shows meaningful clinical activity in patients with intrahepatic cholangiocarcinoma (IHC) containing FGFR2 fusions

According to updated phase II findings presented at the 2018 ESMO Congress, infigratinib, a selective pan-FGFR kinase inhibitor, demonstrated a clinical meaningful activity in patients with IHC.

Source:

2018 ESMO Congress

2018-12-04

A combination therapy can be used to control the disease of osimertinib-resistant lung cancer patients with RET gene fusion

This study indicated that RET fusion mutation is one of the mechanisms of drug resistance in EGFR-mutant lung cancer patients after osimertinib treatment. A combination therapy provides a new strategy to overcome the drug resistance

Source:

Piotrowska Z, et al., Cancer Discov

2018-11-01

FDA Approves Anti-PD-1 Antibody Cemiplimab for CSCC

The U.S. FDA approves PD-1 inhibitor cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC).

Source:

N Engl J Med. &J Clin Oncol.

2018-11-01

Repotrectinib Shows Significant Clinical Activity in ROS1+ NSCLC

In the phase I/II TRIDENT-1 study, repotrectinib demonstrates a clinically meaningful response in non-small cell lung cancer (NSCLC) patients carrying ROS1 fusion.

Source:

The IASLC 19th World Conference on Lung Cancer

2018-11-01

Brigatinib Shows Promising Results as First Line for ALK+ Lung Cancer

In the phase 3 ALTA-1L study, brigatinib significantly prolongs the progression-free survival (PFS) compared to crizotinib in adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Source:

N Engl J Med.

2018-11-01

PARP/Immunotherapy Combo Offers New Opportunities in Ovarian Cancer

There are limited treatment options in platinum-resistance/refractory ovarian cancer patients. The phase I/II TOPACIO/KEYNOTE-162 study shows that the combination of PARP inhibitor and a PD-1 inhibitor can achieve response in difficult-to treat patients.

Source:

J Clin Oncol.

2018-11-01

The Next-Generation Sequencing Data Revealed The Prevalence of Homologous Recombination–related Gene Mutations in Multiple Cancer Types

The scientists analyzed the prevalence of homologous recombination–related gene mutations across 21 cancer types. The sequencing data indicated that these genes were commonly mutated in endometrial, biliary tract, and bladder cancer. The results revealed

Source:

JCO Precis Oncol.